Summary
26.34 -0.90(-3.30%)09/13/2024
Bicycle Therapeutics Ltd (BCYC)
Bicycle Therapeutics Ltd (BCYC)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -3.48 | 28.24 | 17.33 | 8.40 | 3.09 | 29.12 | 170.15 | 119.50 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 26.34 | |
| Open | 27.35 | |
| High | 27.62 | |
| Low | 25.37 | |
| Volume | 722,391 | |
| Change | -0.95 | |
| Change % | -3.48 | |
| Avg Volume (20 Days) | 233,232 | |
| Volume/Avg Volume (20 Days) Ratio | 3.10 | |
| 52 Week Range | 12.54 - 28.10 | |
| Price vs 52 Week High | -6.26% | |
| Price vs 52 Week Low | 110.05% | |
| Range | -3.69 | |
| Gap Up/Down | -0.75 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,863 | |
| EBIDTA | -24,381,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 73.64 | |
| Book Value | 6.6740 | |
| Earnings Per Share | -2.8720 | |
| EPS Estimate Current Quarter | -0.5900 | |
| EPS Estimate Next Quarter | -0.6800 | |
| EPS Estimate Current Year | -2.7200 | |
| EPS Estimate Next Year | -2.8300 | |
| Diluted EPS (TTM) | -2.8720 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -5.4913 | |
| Return on asset (TTM) | -0.1790 | |
| Return on equity (TTM) | -0.4723 | |
| Revenue TTM | 11,774,000 | |
| Revenue per share TTM | 0.5110 | |
| Quarterly Revenue Growth (YOY) | 0.1280 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -22,759,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 8.9839 | |
| Revenue Enterprise Value | 111.1105 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 29,399,700 | |
| Shares Float | 15,508,053 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 13.08 | |
| Institutions (%) | 60.12 | |
09/14 03:00 EST - businesswire.com
Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024
BARCELONA--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated Phase 1/2 clinical results for Bicycle Toxin Conjugate (BTC®) zelenectide pevedotin (formerly BT8009) in metastatic urothelial cancer (mUC); BTC molecule BT5528 in advanced solid tumors, such as mUC and ovarian; and Bicycle Tumor-Targeted Immune Cell Agonist.
Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024
BARCELONA--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated Phase 1/2 clinical results for Bicycle Toxin Conjugate (BTC®) zelenectide pevedotin (formerly BT8009) in metastatic urothelial cancer (mUC); BTC molecule BT5528 in advanced solid tumors, such as mUC and ovarian; and Bicycle Tumor-Targeted Immune Cell Agonist.
09/06 13:37 EST - benzinga.com
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
RBC Capital initiated coverage on Bicycle Therapeutics PLC BCYC, noting an advantage in oncology and beyond.
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
RBC Capital initiated coverage on Bicycle Therapeutics PLC BCYC, noting an advantage in oncology and beyond.
08/20 07:37 EST - seekingalpha.com
Bicycle Therapeutics Is Looking Increasingly Attractive
Bicycle Therapeutics, founded by Nobel laureate Dr. Greg Winter, uses "bicycles", which are smaller, more stable, and cheaper to produce than monoclonal antibodies. BCYC's pipeline includes promising BTC molecules targeting various tumors with differentiated safety profiles and efficacy data. Financially, BCYC has a market cap of $1.54bn, a strong cash balance, an extensive IP portfolio, and collaborations with major pharma companies, making it an attractive investment opportunity.
Bicycle Therapeutics Is Looking Increasingly Attractive
Bicycle Therapeutics, founded by Nobel laureate Dr. Greg Winter, uses "bicycles", which are smaller, more stable, and cheaper to produce than monoclonal antibodies. BCYC's pipeline includes promising BTC molecules targeting various tumors with differentiated safety profiles and efficacy data. Financially, BCYC has a market cap of $1.54bn, a strong cash balance, an extensive IP portfolio, and collaborations with major pharma companies, making it an attractive investment opportunity.
08/09 13:01 EST - zacks.com
What Makes Bicycle Therapeutics (BCYC) a New Buy Stock
Bicycle Therapeutics (BCYC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Bicycle Therapeutics (BCYC) a New Buy Stock
Bicycle Therapeutics (BCYC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
08/09 10:55 EST - zacks.com
Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 88.9% in Bicycle Therapeutics (BCYC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 88.9% in Bicycle Therapeutics (BCYC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
08/01 16:05 EST - businesswire.com
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC) today announced that on August 1, 2024, the Compensation Committee of the company's Board of Directors granted to seven new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 71,200 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering.
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC) today announced that on August 1, 2024, the Compensation Committee of the company's Board of Directors granted to seven new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 71,200 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering.
07/22 07:00 EST - businesswire.com
Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of four abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2024, taking place September 13-17 in Barcelona. Poster Presentation Details: Title: BT8009 monotherapy in enfortumab vedotin-naïv.
Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of four abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2024, taking place September 13-17 in Barcelona. Poster Presentation Details: Title: BT8009 monotherapy in enfortumab vedotin-naïv.
06/27 10:40 EST - zacks.com
Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year?
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year?
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
06/21 09:25 EST - zacks.com
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
06/11 10:40 EST - zacks.com
Is Bicycle Therapeutics (BCYC) Stock Outpacing Its Medical Peers This Year?
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Is Bicycle Therapeutics (BCYC) Stock Outpacing Its Medical Peers This Year?
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
06/03 07:00 EST - businesswire.com
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in the following investor conferences in June: Jefferies Global Healthcare Conference on Wednesday, June 5, 2024; fireside chat at 8:30 a.m. ET Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June.
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in the following investor conferences in June: Jefferies Global Healthcare Conference on Wednesday, June 5, 2024; fireside chat at 8:30 a.m. ET Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June.
05/24 13:25 EST - zacks.com
Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M
Bicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple institutional investors, which is expected to generate gross proceeds of $555 million.
Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M
Bicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple institutional investors, which is expected to generate gross proceeds of $555 million.
05/24 10:56 EST - zacks.com
Wall Street Analysts Think Bicycle Therapeutics (BCYC) Could Surge 85.52%: Read This Before Placing a Bet
The consensus price target hints at an 85.5% upside potential for Bicycle Therapeutics (BCYC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Bicycle Therapeutics (BCYC) Could Surge 85.52%: Read This Before Placing a Bet
The consensus price target hints at an 85.5% upside potential for Bicycle Therapeutics (BCYC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
05/23 17:05 EST - businesswire.com
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that emerging Phase 1/2 clinical pharmacokinetic (PK) and safety data for Bicycle Toxin Conjugates® (BTC® molecules) BT8009 and BT5528 demonstrating differentiated safety and tolerability profiles will be presented at the 2024 American Society for.
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that emerging Phase 1/2 clinical pharmacokinetic (PK) and safety data for Bicycle Toxin Conjugates® (BTC® molecules) BT8009 and BT5528 demonstrating differentiated safety and tolerability profiles will be presented at the 2024 American Society for.
05/23 07:00 EST - businesswire.com
Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 25,933,706 American Depositary Shares (“ADSs”), each representing one ordinary share, and in lieu.
Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 25,933,706 American Depositary Shares (“ADSs”), each representing one ordinary share, and in lieu.
05/21 10:46 EST - zacks.com
Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year?
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Ocugen (OCGN) have performed compared to their sector so far this year.
Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year?
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Ocugen (OCGN) have performed compared to their sector so far this year.
05/06 13:01 EST - zacks.com
Bicycle Therapeutics (BCYC) Moves to Buy: Rationale Behind the Upgrade
Bicycle Therapeutics (BCYC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bicycle Therapeutics (BCYC) Moves to Buy: Rationale Behind the Upgrade
Bicycle Therapeutics (BCYC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
05/06 10:56 EST - zacks.com
Wall Street Analysts See a 77.22% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 77.2% in Bicycle Therapeutics (BCYC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 77.22% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 77.2% in Bicycle Therapeutics (BCYC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
04/24 10:05 EST - businesswire.com
Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of two abstracts for poster presentation at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago. Poster Presentation Details: Title: Breaking from the paradigm of antibody-d.
Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of two abstracts for poster presentation at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago. Poster Presentation Details: Title: Breaking from the paradigm of antibody-d.
04/02 07:00 EST - businesswire.com
Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024, at 11 a.m. ET. A live webcast of the fireside chat will be accessible from the Investor section of the company's websi.
Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024, at 11 a.m. ET. A live webcast of the fireside chat will be accessible from the Investor section of the company's websi.